PRAMIPEXOLE GxP pramipexole dihydrochloride 0.25 mg tablets blister pack

Country: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

pramipexole dihydrochloride monohydrate, Quantity: 0.25 mg

Disponibbli minn:

Arrotex Pharmaceuticals Pty Ltd

INN (Isem Internazzjonali):

pramipexole dihydrochloride monohydrate

Għamla farmaċewtika:

Tablet, uncoated

Kompożizzjoni:

Excipient Ingredients: mannitol; pregelatinised maize starch; magnesium stearate; povidone; silicon dioxide

Rotta amministrattiva:

Oral

Unitajiet fil-pakkett:

10, 30, 100

Tip ta 'preskrizzjoni:

(S4) Prescription Only Medicine

Indikazzjonijiet terapewtiċi:

Pramipexole tablets are indicated for:,-the treatment of signs and symptoms of idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopa.

Sommarju tal-prodott:

Visual Identification: White, oval, uncoated tablets debossed with 'CL' and '3' on one side with breakline in between and a breakline on the other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

L-istatus ta 'awtorizzazzjoni:

Licence status A

Data ta 'l-awtorizzazzjoni:

2014-09-23